DarioHealth AI Platform Targets 10-15% Revenue Growth from Existing Clients
DarioHealth's DarioIQ AI engine is positioned to lift B2B2C recurring revenue 10-15% from current customers while the AI healthcare market expands rapidly toward hundreds of billions.AI Engine Delivers Engagement Gains as Recurring Revenue Outlook Climbs
DarioHealth Corp. (DRIO:NASDAQ) said its DarioIQ platform reflects the ongoing digital health rotation and AI transformation across healthcare, with broader deployment expected to increase recurring revenue from existing customers by 10% to 15%.Pet Odor Market Ignites BioLargo Consumer Comeback
BioLargo re-enters the booming U.S. pet odor control market with a direct-to-consumer CupriDyne brand, building on proven demand while advancing water treatment and medical technologies for retail investors.Cleantech Co. Relaunches Pet Brand Under Its Own Control
BioLargo Inc. (BLGO:OTCQX) unveils plans to reintroduce its enormously popular CupriDyne-based pet odor products to the consumer market. This time, the company says it will own the brand and do it its own way. This article is issued on behalf of Dyadic International Inc. Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation
Contributed Technical Analyst Opinion Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. (DYAI:NASDAQ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.
Satellos Bioscience Delivers Promising DMD Data With Fast Track Win
Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity.Biotech With Muscle Disease Drug Uncovers Results in Trial Data
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data.Digital Health Platform Lands Access to Hundreds of Thousands of Covered Lives
DarioHealth Corp. (DRIO:NASDAQ) signed a new agreement through its Amwell partnership that makes its cardiometabolic platform available to a major Arizona health insurer's ASO business, representing hundreds of thousands of covered lives.NASDAQ-Listed Duchenne Muscular Dystrophy Drugmaker Wins FDA Filing Acceptance Despite Confirmatory Trial Miss
Research Report
The FDA accepted the company's morpholino oligomer filings with a February 2027 PDUFA date, but a missed confirmatory trial endpoint clouds its path to full approval. Grey Matters Health Inc. Targets Alzheimer's PET Imaging Opportunity
Grey Matters Health Inc. advances first U.S. brain-dedicated PET clinic for Alzheimer's detection amid surging diagnostics demand. Learn the key facts for investors.BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew
BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives.First-of-Its-Kind US Brain Imaging Clinic Takes Delivery of Key PET Scanner
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) received its first brain-dedicated PET scanning system for its flagship Florida NovaScan Neuroimaging Clinic, which the company said will be the first U.S. facility dedicated to brain-only PET imaging for Alzheimer's disease and other neurological conditions.Air Force Bases Renew Their Contracts With Cleantech Pioneer
Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) says its engineering division has secured contract renewals worth over US$1.4 million. Find out why experts like this technology incubator's structure.French Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filing
Research Report
A Wedbush analyst raised its target on a French biopharma's ulcerative colitis candidate but disputed bullish efficacy claims, flagging Jak competition and a 2027 Crohn's readout. 






















































